Dr Klayne Rasmussn, PHD | |
814 Mahogany Dr, Fruit Heights, UT 84037-4409 | |
(801) 544-2470 | |
Not Available |
Full Name | Dr Klayne Rasmussn |
---|---|
Gender | Male |
Speciality | Marriage & Family Therapist |
Location | 814 Mahogany Dr, Fruit Heights, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1831333988 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 329754-3902 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Klayne Rasmussn, PHD 814 Mahogany Dr, Fruit Heights, UT 84037-4409 Ph: (801) 544-2470 | Dr Klayne Rasmussn, PHD 814 Mahogany Dr, Fruit Heights, UT 84037-4409 Ph: (801) 544-2470 |
News Archive
Although vaccination programmes against pertussis are very effective in Europe, new Finnish study shows that the disease is still very common among middle-aged adults in various European countries.
In the midst of an unprecedented Zika crisis in Brazil, there were a few flickers of hope: Some babies appeared to be normal at birth, free of devastating birth defects that affected other Brazilian children exposed to the virus in utero.
New research has traced elevated levels of a specific compound in the brain to problem-solving deficits in patients with schizophrenia.
Pharmaceutical poisoning remains a common childhood injury, despite years of concerted prevention efforts, such as improved safe guards on packaging. Over half a million children are exposed to pharmaceuticals each year. A new study soon to be published in The Journal of Pediatrics attempts to understand this growing problem to aid in the progress of reducing the number of childhood injuries due to pharmaceutical poisoning.
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since 2015 also for the treatment of adults with Waldenström macroglobulinaemia. Regarding the treatment of patients with CLL or MCL, the Federal Joint Committee (G-BA) already conducted a benefit assessment and made a decision in 2015.
› Verified 4 days ago